Chevy Chase Trust Holdings LLC Has $16.24 Million Stake in Humana Inc. (NYSE:HUM)

Chevy Chase Trust Holdings LLC decreased its position in Humana Inc. (NYSE:HUM) by 2.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 64,005 shares of the insurance provider’s stock after selling 1,373 shares during the period. Chevy Chase Trust Holdings LLC’s holdings in Humana were worth $16,239,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Creative Financial Designs Inc. ADV grew its position in Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after buying an additional 61 shares in the last quarter. Ashton Thomas Securities LLC acquired a new stake in Humana during the third quarter worth approximately $31,000. Your Advocates Ltd. LLP grew its position in Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares in the last quarter. Atwood & Palmer Inc. grew its position in Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after buying an additional 60 shares in the last quarter. Finally, LRI Investments LLC grew its position in Humana by 1,021.4% during the third quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock worth $50,000 after buying an additional 143 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on HUM. Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 price target on shares of Humana in a research report on Wednesday. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and increased their price target for the stock from $247.00 to $308.00 in a research report on Wednesday, November 6th. Morgan Stanley reduced their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Barclays upped their target price on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday. Finally, Royal Bank of Canada restated an “outperform” rating and set a $283.00 target price on shares of Humana in a research note on Wednesday. Nineteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Humana has an average rating of “Hold” and a consensus target price of $293.05.

Insider Activity at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.32% of the stock is currently owned by company insiders.

Humana Stock Up 0.3 %

Shares of HUM opened at $253.61 on Friday. The stock has a market capitalization of $30.54 billion, a price-to-earnings ratio of 22.46, a PEG ratio of 2.11 and a beta of 0.56. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46. The stock has a fifty day moving average of $271.27 and a 200-day moving average of $294.21. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM) last posted its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, sell-side analysts anticipate that Humana Inc. will post 16.11 earnings per share for the current fiscal year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.